Morgan Stanley restated their hold rating on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) in a report published on Monday.
IRWD has been the topic of a number of other research reports. BidaskClub raised Ironwood Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, August 25th. ValuEngine raised Ironwood Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, September 1st. Mizuho reissued a buy rating and set a $20.00 price target (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, August 25th. Credit Suisse Group initiated coverage on Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a buy rating and a $19.00 price target on the stock. Finally, Cowen set a $20.00 price target on Ironwood Pharmaceuticals and gave the stock a buy rating in a research report on Monday, August 21st. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $17.88.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down $0.03 during trading hours on Monday, reaching $15.09. The company had a trading volume of 1,271,000 shares, compared to its average volume of 1,308,549. Ironwood Pharmaceuticals has a 1-year low of $13.43 and a 1-year high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. The business had revenue of $86.80 million for the quarter, compared to the consensus estimate of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The firm’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.18) earnings per share. analysts anticipate that Ironwood Pharmaceuticals will post -1.12 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRWD. Gerber Kawasaki Wealth & Investment Management bought a new stake in Ironwood Pharmaceuticals during the third quarter worth $170,000. Teacher Retirement System of Texas bought a new stake in Ironwood Pharmaceuticals during the second quarter worth $192,000. Strs Ohio lifted its stake in Ironwood Pharmaceuticals by 63.1% during the second quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 4,100 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 648 shares during the last quarter. Finally, Aperio Group LLC lifted its stake in Ironwood Pharmaceuticals by 11.9% during the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2017/12/08/ironwood-pharmaceuticals-irwd-given-hold-rating-at-morgan-stanley.html.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.